ProFound AI Risk and PowerLook Density Assessment are the latest updates to iCAD's Breast Health Solutions suite, which also includes the Company's leading-edge cancer detection software, ProFound AI®. In 2018, ProFound AI for DBT became the first artificial intelligence (AI) software application trained using deep learning technology on DBT images to be FDA cleared. It offers clinically proven time-savings benefits to radiologists, reducing reading time by 52.7 percent, while also improving radiologist sensitivity by 8 percent, and reducing false positives and unnecessary patient recall rates by 7.2 percent.[14]
About iCAD, Inc.
Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions.
Back to HCB News
